There are currently 476 clinical trials in Rochester, New York looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Rochester, University of Rochester Medical Center, James P. Wilmot Cancer Center at University of Rochester Medical Center and Rochester Clinical Research, Inc.. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
NCT04488081
Recruiting
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: COVID-19
Register for Updates
Insertable Cardiac Monitor for Primary Atrial Fibrillation Detection in High-Risk Heart Failure Patients
NCT04818645
Recruiting
Patients with heart failure (HF) represent a large population of patients who are at high risk for complications related to undiagnosed atrial fibrillation (AF). However, currently there are limited modalities for early AF detection and subsequent stroke prevention in this high-risk population. An implantable cardiac monitor (ICM) is inserted subcutaneously and can provide long term arrhythmia information via remote monitoring. The ASSERT-AF study seeks to accurately define the burden of AF and... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Atrial Fibrillation, Heart Failure
Register for Updates
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS
NCT04278768
Recruiting
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). Patients enrolling in the Phase 1 portion of the study must meet one of the following criteria prior to consenting to the study: R/R AML with FLT3 mutations who have been previously treated with a FLT3 inhibitor R/R AML with spliceosome mutations of SF3B1 or... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Register for Updates
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT04886531
Recruiting
Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone or the combination of neratinib and an aromatase inhibitor. A breast biopsy will be performed prior to Day 1 of week 4 of treatment. Following surgery, patients will receive standard of care HER2-directed and endocrine therapy at the treating physician's discretion.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
Register for Updates
A New Sildenafil Oral Film in Patients With Erectile Dysfunction
NCT05490680
Recruiting
This is a Phase III, prospective, interventional, multi-center, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical study required by FDA to demonstrate the efficacy and safety of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg as compared to placebo in approximately 488 men clinically diagnosed with erectile dysfunction (ED).
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: Rochester Clinical Research, Inc, Rochester, New York
Conditions: Erectile Dysfunction
Register for Updates
A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain
NCT04504812
Recruiting
There is an urgent public health need to reduce reliance on opioids for effective long-term pain management, particularly in knee osteoarthritis (KOA). This effectiveness trial will compare commonly recommended treatments to reduce pain and functional limitations in KOA.These results will lead to improved patient selection for treatment and inform evidence based guidelines by offering well-tested, effective, non-surgical alternatives.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Knee Osteoarthritis
Register for Updates
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
NCT00539162
Recruiting
The goal of this clinical research study is to evaluate a method involving a blood test, called CA-125, that may be helpful in the early detection of ovarian cancer in women who are at low risk.
Gender:
Female
Ages:
Between 50 years and 74 years
Trial Updated:
03/07/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Ovarian Cancer
Register for Updates
Open-Label of SPN-820 in Adults With Major Depressive Disorder
NCT06235905
Recruiting
This study will evaluate the efficacy and safety of SPN-820 in Adults With Major Depressive Disorder (MDD)
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/06/2024
Locations: Muhammad Saleem Ismail, Rochester, New York
Conditions: Major Depressive Disorder
Register for Updates
A Single Arm Pilot Trial of a Social Network Intervention
NCT05745038
Recruiting
The purpose of this study is to see if a social network support program (SOcial Networks to Activate Trust & Adherence or SONATA) is helpful for older individuals receiving cancer treatment. The SONATA program will last for about 4 months. There are a total of 6 coaching sessions. The first 5 sessions will be held approximately every 1 to 2 weeks. Session 6 or the final session will be held approximately 1 to 2 months after session 5. Each session will last for about 1 to 2 hours.
Gender:
All
Ages:
65 years and above
Trial Updated:
03/05/2024
Locations: University of Rochester, Rochester, New York
Conditions: Cancer
Register for Updates
Study Comparing Two Different Schedules of Radiation for Early-stage Lung Cancer
NCT03706027
Recruiting
This study's goal is to find out if the kind of side effects people experience from radiation is different depending on the schedule of their radiation treatment. Patients will be randomly assigned to either the 3 Fraction or 5 Fraction schedule of radiation. After patients complete radiation treatment, they will follow up with their radiation oncologist.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/05/2024
Locations: James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York
Conditions: Lung Cancer
Register for Updates
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
NCT05210790
Recruiting
The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/03/2024
Locations: Wilmot Cancer Institute, University of Rochester, Rochester, New York
Conditions: Polycythemia Vera
Register for Updates
Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)
NCT02633163
Recruiting
The purpose of this study is to evaluate the efficacy and safety of mesenchymal stem cells (MSCs) obtained from umbilical cords for the treatment of adults with systemic lupus erythematosus (SLE). The goal of this study is to determine if patients receiving an MSC infusion plus standard of care respond better than patients receiving placebo infusion plus standard of care.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/29/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Systemic Lupus Erythematosus
Register for Updates